Product Images Venlafaxine Hydrochloride

The generated text seems to be a mix of random letters, numbers, and symbols. Hence, the description cannot be formed from it.*

This is a description of a medication called Venlafaxine Hydrochloride Extended-release Capsules USP. It comes in a package of 30 capsules and is identified by the NDC code 42291-896.30. The scan also includes some unreadable characters and other miscellaneous text that is not relevant to the medication description.*

This text appears to be a combination of random characters and words. Therefore, the description cannot be generated as the text provided is not readable.*

This text appears to be a table listing drugs that interact with each other, as well as their recommended usage and any side effects or cautions that should be taken into consideration when taken in combination. The drugs listed include ethanol, Diazepam, Cimetidine, Ketoconazole, Indinavir, Metoprolol, Imipramine, Lithium, and Venlafaxine. The table also includes peak concentration values (cmax) and area under the curve (AUC) values for each drug interaction. The table recommends avoiding concurrent use of some drugs, using caution in patients with certain conditions, and monitoring blood pressure in some cases.*

This text pertains to pharmacokinetics of various drugs in special populations such as those with hepatic impairment, renal impairment, CYP2D6 polymorphism, age, and gender. The fold change and 90% CI recommendation for the drugs and populations are provided, with indications for necessary dose adjustments in certain cases. There is a figure depicting the pharmacokinetics of venlafaxine and its metabolite O-desmethylvenlafaxine (ODV) in special populations.*

Table 10 displays the changes in Supine Systolic and Diastolic Blood Pressure (measured in mm Hg) for patients on Venlafaxine Hydrochloride Extended-release Capsules and Placebo in controlled studies. The table showcases the mean changes from baseline in blood pressure for Venlafaxine Hydrochloride Extended-release Capsules at doses of <75mg per day and >75mg per day along with Placebo across various indications of treatment varying from 6 to 12 weeks.*

Table 12 shows the approximate mean final on-therapy increase in pulse rate (beats/min) caused by Venlafaxine Hydrochloride Extended-release Capsules in premarketing placebo-controlled studies with different durations for various indications. The indications include MDD, GAD, SAD, and PD, and the duration range from 8-12 weeks. The table provides data on the pulse rate increase for the Venlafaxine Hydrochloride Extended-release Capsules compared to the placebo.*

Table 13 shows the mean final on-therapy changes in cholesterol concentrations (mg/dL) during premarketing studies of Venlafaxine Hydrochloride extended-release capsules for major depressive disorder (MDD) and generalized anxiety disorder (GAD). The table displays the indication for the medication, the duration of the study, and the corresponding changes in cholesterol levels.*

Table 14: Mean final on-therapy increases in Triglyceride concentrations (mg/dL) in Venlafaxine Hydrochloride premarketing studies. The table shows the mean final increase in Triglyceride concentration for different indications (duration) and the medication (Venlafaxine Hydrochloride extended-release capsules) compared to the placebo. The indications include SAD (12 weeks and 6 months) and P (12 weeks and 6 months).*

This appears to be a table indicating the percentage of patients 65 years and older who were studied for various indications and treated with Venlafaxine Hydrochloride Extended Release Capsules. The indications listed include MDD (Major Depressive Disorder), E (Generalized Anxiety Disorder), and P (Social Anxiety Disorder). The numbers in parentheses appear to represent the actual number of patients studied for each indication.*

Table 17 presents data for major depressive disorder studies. The table lists study numbers and treatment groups and their corresponding primary efficacy measure, which is the HANKD score. Mean Baseline LS, Mean Change, Placebo Score (SD) from Baseline Subtracted Difference are also included in the table. The table shows that Venlofaxine Hydrochloride Extended-release Capsules (75 10 225 mg/day) were statistically significantly superior to placebo in Study 1 and Study 2. Meanwhile, in Study 3 Venlofxine Immediate Release Tablets (15010 375 mg/day) were not superior to placebo.*

This is a table presenting the results of four studies related to the treatment of Generalized Anxiety Disorder. The primary efficacy measure was HAMD score. The table includes the mean baseline score, mean change from baseline, and placebo-subtracted difference for each group in the study. The different dosage treatments show varying levels of effectiveness, and some are statistically significant compared to the placebo. There is no further information provided.*

Table 19 provides data on the efficacy of VenXR in treating Social Anxiety Disorder. The table includes information on different studies that were conducted to evaluate the drug's effectiveness. The primary efficacy measure used in these studies was LSAS Score, and the table presents the mean baseline and mean change scores for each treatment group, along with the placebo-subtracted differences. The data shows that VenXR was statistically significantly superior to placebo in all the studies mentioned. The table also includes some statistical measures such as standard deviation, standard error, least-squares mean, and confidence interval.*

This is a table showing the incidence of Mania or Hypomania reported in Venlafaxine Hydrochloride Extended-release Capsules treated patients in pre-marketing studies for various indications such as MDD, GAD, SAD, and P. The percentages are given for both the medication and the placebo group.*

The table presents data from two studies on Panic Disorder. Study 1 and Study 2 both compare the efficacy of two different doses of Ven (Ven XR75 mgt and Ven R 150 mgt or Ven XR75 mgt and Ven XR 225 mgt, respectively) to a placebo group. The primary efficacy measure was the percentage of patients who were free of full-symptom panic attacks. The table reports the percent of patients who met that measure, as well as adjusted odds ratios and confidence intervals. It notes that one dose was statistically significantly superior to placebo.*

The text is a set of tables presenting the average change in body weight and incidence of weight loss in pediatric patients in double-blind, placebo-controlled studies of Venlafaxine Hydrochloride Extended-release Capsules. The tables indicate that Venlafaxine Hydrochloride results in less weight loss than the placebo group.*

The text shows a table containing average height increases (in cm) of pediatric patients in placebo-controlled trials of Venlafaxine Hydrochloride Extended-release Capsules for Major Depressive Disorder (MDD). Different durations of treatment (6D, 04 weeks, and 16 weeks) are shown, along with the corresponding number of patients in each group. The table also includes a significance level (p-value) of 0.041.*

This is a table presenting the incidence rates of decreased appetite and associated discontinuation rates in pediatric patients receiving Venlafaxine Hydrochloride Extended-release Capsules in placebo-controlled studies. The table reports incidence and discontinuation rates for different durations and indications including MDD, GAD, and SAD. The text also mentions that the discontinuation rates for weight loss were the same in both treatment and placebo groups.*

The provided text is a table showing the incidence (%) of patients reporting adverse reactions leading to discontinuation in placebo-controlled clinical studies (up to 12 weeks duration) for Venlofaxine Hydrochloride extended-release capsules and Placebo. The table details different body systems examined for 8 different adverse reactions, including Asheria, Headache, Nausea, Dizziness, Insomnia, Somnolence, Skin and appendages, and Sweating. The percentage of patients reporting the adverse reaction is provided for both Venlofaxine Hydrochloride extended-release capsules and Placebo.*

This table provides information on the number of patients who received Venlafaxine Hydrochloride Extended-release Capsules in premarketing clinical studies for Major Depressive Disorder (MDD) indication. A total of 1314 patients received the medication for this indication. Additionally, the pre-marketing assessment of Venlafaxine tablets involved multiple doses being administered to 2,897 patients in studies for MDD.*

Table 9 shows the common adverse reactions in patients reporting adverse reactions (>2% and >placebo) in placebo-controlled studies across all indications for up to 12 weeks duration while taking Venlafaxine Hydrochloride Extended-Release Capsules compared to a Placebo. The adverse reactions are categorized based on Body System including Body as a whole, Cardiovascular system, Digestive system, Nervous system, Respiratory system, Skin and appendages, and Special senses, and Urogenital system. The percentages of patients reporting the adverse reactions are provided for both Venlafaxine Hydrochloride Extended-Release Capsules and Placebo separately.*